论文部分内容阅读
骨质疏松是以骨量减低、易发骨折为特征的代谢性疾病,近年来在我国发病率不断上升。骨质疏松的经典综合治疗方法中采用的药物或多或少存在一些缺点,限制了药物的长期使用、适用人群,一定程度上影响了治疗效果。本文综述了近年出现的骨质疏松生物治疗相关的RANKL/RANK/OPG信号通路,介绍了其代表性生物治疗药物狄诺塞麦研究进展。生物治疗以其靶向性、高效性的特点,在未来骨质疏松防治过程中将发挥重要作用。
Osteoporosis is a metabolic disease characterized by reduced bone mass and fracture-prone fractures. The incidence of osteoporosis in China has been on the rise in recent years. The drugs used in the classic comprehensive treatment of osteoporosis have more or less shortcomings, which limit the long-term use of drugs and apply to the population, to a certain extent, affect the treatment effect. This review summarizes the RANKL / RANK / OPG signaling pathways involved in the treatment of osteoporosis in recent years and presents the progress of the study on denosumab, a representative biotherapeutic drug. Biological therapy with its targeted and efficient features in the future prevention and treatment of osteoporosis will play an important role.